TPOXX (tecovirimat)
Treatment of Smallpox
Key Facts
About Siga
SIGA Technologies is a commercial-stage biopharmaceutical company with a critical mission to protect against high-consequence infectious disease threats, primarily orthopoxviruses. Its strategy is built on proactive preparedness and government partnerships, most successfully demonstrated by its lead product, TPOXX® (tecovirimat), which is a cornerstone of the U.S. Strategic National Stockpile and approved in multiple regions. The company has established a defensible niche in global health security, generating $139M in 2024 revenue through sales to over 30 countries, while advancing its pipeline into new indications and formulations.
View full company profileAbout Siga
SIGA Technologies is a commercial-stage biopharmaceutical company with a critical mission to protect against high-consequence infectious disease threats, primarily orthopoxviruses. Its strategy is built on proactive preparedness and government partnerships, most successfully demonstrated by its lead product, TPOXX® (tecovirimat), which is a cornerstone of the U.S. Strategic National Stockpile and approved in multiple regions. The company has established a defensible niche in global health security, generating $139M in 2024 revenue through sales to over 30 countries, while advancing its pipeline into new indications and formulations.
View full company profileAbout SIGA Technologies
SIGA Technologies' mission is to protect humanity against severe infectious diseases by developing and commercializing critical medical countermeasures. Its core achievement is the successful development and regulatory approval of TPOXX® (tecovirimat), the first oral antiviral for smallpox, which forms the cornerstone of a durable, government-focused revenue stream. The company's strategy is to deepen its role as an essential biodefense partner to the U.S. and allied governments while expanding TPOXX's label into new indications like post-exposure prophylaxis and pediatric use, thereby solidifying its market leadership in the orthopoxvirus space.
View full company profileAbout SIGA Technologies
SIGA Technologies' mission is to protect humanity against severe infectious diseases by developing and commercializing critical medical countermeasures. Its core achievement is the successful development and regulatory approval of TPOXX® (tecovirimat), the first oral antiviral for smallpox, which forms the cornerstone of a durable, government-focused revenue stream. The company's strategy is to deepen its role as an essential biodefense partner to the U.S. and allied governments while expanding TPOXX's label into new indications like post-exposure prophylaxis and pediatric use, thereby solidifying its market leadership in the orthopoxvirus space.
View full company profileAbout SIGA Technologies
SIGA Technologies' mission is to protect humanity against severe infectious diseases by developing and commercializing critical medical countermeasures. Its core achievement is the successful development and regulatory approval of TPOXX® (tecovirimat), the first oral antiviral for smallpox, which forms the cornerstone of a durable, government-focused revenue stream. The company's strategy is to deepen its role as an essential biodefense partner to the U.S. and allied governments while expanding TPOXX's label into new indications like post-exposure prophylaxis and pediatric use, thereby solidifying its market leadership in the orthopoxvirus space.
View full company profileTherapeutic Areas
Other Treatment of Smallpox Drugs
| Drug | Company | Phase |
|---|---|---|
| TPOXX (tecovirimat) Oral | SIGA Technologies | Approved |
| TPOXX (tecovirimat) IV | SIGA Technologies | Approved |